Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients w ith Advanced Gastric Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients. Materials and Methods: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1∼2. The treatment was repeated at 2 week intervals. Results: The median age of the patients was 50 years (range: 31∼74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5 ∼32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6∼4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9∼9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most com - mon non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths. Conclusion: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.
Abstract
Purpose: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients. Materials and Methods: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1∼2. The treatment was repeated at 2 week intervals. Results: The median age of the patients was 50 years (range: 31∼74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5 ∼32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6∼4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9∼9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most com - mon non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths. Conclusion: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.
참고문헌 (23)
- "2001 Annual reportof the Korea central cancer registry: based on registred datafrom 134 hospitals.", 36, pp.19~30 (2004)
- "Glimelius B; SBU-group.swedish council of technology assessment in health care. Asystemic overview of chemotherapy effects in gastric cancer", 40, pp.309~26 (2001)
- "Systemic treatment of gastriccancer", 16, pp.255~63 (2004)
- "A phase II study of weekly docetaxel as salvagechemotherapy for advanced gastric cancer", 11, pp.1263~6 (2000)
- "Weekly irinotecan in patients with metastatic gastric cancerfailing cisplatin-based chemotherapy", 34, pp.8~13 (2004)
- "Docetaxel plus cisplatin as second-line therapy in metastaticor recurrent advanced gastric cancer progressing on 5-FUbased regimen", 27, pp.477~80 (2004)
- "Cellular determinants of oxaliplatin sensitivity in colon cancercell lines", 39, pp.112~9 (2003)
- "Apoptosis induced by oxaliplatin in human coloncancer HCT15 cell line", 24, pp.219~26 (2004)
- "Bolus fluorouracil and leucovorin withoxaliplatin as first-line treatment in metastatic colorectalcancer", 20, pp.2545~50 (2002)
- "Oxaliplatin-induced damage of cellularDNA", 58, pp.920~7 (2000)
- "Role of cancer ligand in platinumresistance of human carcinoma cell lines", 53, pp.799~805 (1993)
- "Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinomacell lines", 54, pp.3500~5 (1994)
- "Phase I study of oxaliplatin in patients with advanced cancer", 25, pp.299~303 (1990)
- "Randomized controlled trial offluorouracil plus leucovorin,irinotecan,and oxaliplatin combinationsin patients with previously untreated metastaticcolorectal cancer", 22, pp.23~30 (2004)
- "Superiority of oxaliplatin andfluorouracil- leucovorin compared with either therapy alone inpatients with progressive colorectal cancer after irinotecan andfluorouracil- leucovorin: interim results of a Phase III Trial.", 21, pp.2059~69 (2003)
- "Phase II study of oxaliplatin, 5-fluorouracil and leucovorinin previously platinum-treated patients with advanced gastriccancer", 14, pp.383~7 (2003)
- "Phase II study of weekly oxaliplatin and 24-h infusionof high-dose 5-fluorouracil and folinic acid in the treatment ofadvanced gastric cancer", 91, pp.453~8 (2004)
- "Phase II study of oxaliplatin,fluorouracil,andfolinic acid in locally advanced or metastatic gastric cancerpatients", 20, pp.4543~48 (2002)
- "Phase II trial of biweeklyinfusional fluorouracil,folinic acid,and oxaliplatin in patientswith advanced gastric cancer", 22, pp.658~63 (2004)
- "Reportingresults of cancer treatment", 47, pp.207~14 (1981)
- "Optimal two-stage designs for phase II clinical trials", 10, pp.1~10 (1989)
- "Oxaliplatin with biweekly, low dose leucovorin and bolusand continuous infusion 5-fluorouracil (Modified FOLFOX 4)as first-line therapy for patients with metastatic colorectalcancer.", 36, pp.115~20 (2004)
- "Pharmacokineticsand safety profile of oxaliplatin", 25, pp.13~22 (1998)